CHEK1

The bull case

1. 1.

   Strongest genetic validation in the set. DepMap mean gene effect -1.7664, essential in 99.92% of 1,208 models (dependency fraction 0.9992). If a target's worth is its dependency, CHK1 is unambiguous.

   confidence: high·genetic_validation

2. 2.

   Deep chemical tractability. 157 distinct compounds with activity — a mature small-molecule effort exists.

   confidence: high·competitive_landscape

3. 3.

   Renewed momentum. emerging_signals flags a patent surge (z = 2.14) — 44 recent filings vs a 20.5 baseline. Interest is rising, not decaying.

   confidence: moderate·emerging_signals

4. 4.

   Structurally actionable. AlphaMissense flags 58.1% of 9,044 variants pathogenic (hotspot residue 148); Foldseek neighbours present.

   confidence: high·genetic_validation.variant_pathogenicity

The bear case

1. 1.

   A clinical graveyard. Max clinical phase reached = 2. Of 157 compounds, 146 are preclinical and 6 reach phase 2 — zero past it, despite 294 patents. This is a repeated-failure signature.

   confidence: high·competitive_landscape.compound_phase_distribution

2. 2.

   Pan-essentiality is the trap, not the prize. The same 99.9% dependency that validates CHK1 means it is essential in normal proliferating tissue — the textbook cause of an unmanageable therapeutic window, and the most parsimonious explanation for Bear #1.

   confidence: high·genetic_validation, interpreted

3. 3.

   Incumbent shadow. The patent set is concentrated in Bayer entities (top assignees are all Bayer) — a dominant incumbent rather than an open field.

   confidence: moderate·competitive_landscape.top_organizations

4. 4.

   Resistance durability unknowable. The graph has only one curated resistance hit — CHEK2, its own paralog — so combination/durability cannot be assessed.

   confidence: flagged·resistance_bypass_map

The non-consensus angleNo strong angle

No strong non-consensus signal in current data; CHEK1's profile largely matches its reputation. No DepMap co-essentiality fired and the resistance map is empty — there is no differentiated finding to headline. Presenting one would be dressing up consensus.

• A coherent but PPI-proxy checkpoint cluster. The functional-coupling whitespace tool returns CDC25A, CDC25C, CLSPN, RAD51, CDC45, TIMELESS, TOPBP1 (PPI 0.99+) — CHK1's checkpoint-activation and substrate partners. None is in Mosaic's curated target set, so the graph holds no patent/compound data on them; their competitive status is not assessed (not a whitespace claim). This is PPI-proxy coupling — essentially the known DDR network — not a co-dependency finding; it is not advanced as differentiated insight.

  confidence: PPI-proxy — weak·kg_native.synthetic_lethal_whitespace (PPI-proxy)

  Patent / compound status: not assessed (out of coverage). gene outside Mosaic curated coverage — competitive landscape is a validated lead to verify externally, not a whitespace claim.

• A patent surge into a graveyard — a caution, not a buy. emerging_signals flags a patent surge (z = 2.14; 44 recent vs 20.47 baseline), but it is rising interest in a target that has never cleared phase 2 — read as crowding risk, not validation.

  confidence: moderate·kg_native.emerging_signals_self

What would change this thesis

• If any CHK1 asset clears phase 3, the graveyard bear (and the pan-essentiality-window argument) collapses — the window problem would be shown solvable.
• If a tumor-selective dependency subset (e.g. a genotype where CHK1 dependency is high but normal-tissue is spared) is evidenced, Bear #2 weakens decisively.
• External verification of CDC25A / CLSPN / TOPBP1 competitive status — these genes are outside Mosaic's curated coverage, so the graph cannot tell whether the checkpoint module is genuinely open; verify externally before treating it as whitespace.
• If curated resistance literature accumulates, the durability gap (Bear #4) becomes assessable.